

We need you at the Zoo on the 28th June!



CROWDFINDERS

BOOK HERE

Crowdfinders. Who'll be in the Zoo on the 28th June?

Join us, our Partners, the EIS Association and other animals for a wild day of strategic encounters, keynote presentations, discussions, live pitches, wild & wonderful entertainment and, of course, feeding time (BBQ style), at the financial event of the year!

There are a few tickets remaining so if you're a business looking for guidance and funding, an active investor looking to discover exclusive and exciting new opportunities or a professional looking to meet some of the UK's most dynamic prospects in the flesh, we all need to see YOU at "Who's who in the Zoo!"

Book Now with our amazing '25%' discount.

Who's Who in the Zoo...? Active Inspiration, that's Who!

Active inspiration

Healthy people IS good business...and a good investment!

We are a new breed of health tech company.

Ai's mission is to use data to motivate and incentivise employees to be more active.

Evidence that physically healthy staff are more effective is credible and physical well-being is a growth area in employee relations world-wide.

Exploiting this market, Ai delivers a bespoke, flexible, challenge-based exercise service to companies through its app **Fuell**.

- **Fuell** works with iOS and Android, wearables (Apple Watch, Fitbit, Garmin) and third party apps (Strava, runkeeper).
- It is Challenge-based, allowing companies to offer employees any number of Challenges (walking, running, cycling and swimming – anything that can be tracked) and anyone can create their own challenge and invite their colleagues.
- The app can be white-labelled and delivers a management dashboard with real-time data showing the progress and success of Challenges.
- No other product offers a self-service, personalised bespoke service with this level of flexibility.

A partnership with Garmin also gives Ai the leverage to offer heavily discounted Garmin product to companies and their employees.

Created and originally funded through Oxford University and the European Space Agency, current shareholders funded the development of the platform and app now used by a growing number of small and blue chip companies with staff numbers of 10 to 140,000 people.

Ai is now raising funding (from shareholders and new investors) to supercharge the marketing and sales process on a product that has a proven track record and is streets ahead of its rivals.

Ai will be presenting at the Who's Who in the Zoo event on 28th June. Make sure you register for the **'The Crowdfinders Charity Exercise Challenge'** which starts on the 13th June.

Fancy a challenge?

In association with Active Inspiration and their innovative fitness app, Fuell, Crowdfinders proudly presents, 'The Crowdfinders Charity Exercise Challenge'.

In the run up to the "Who's who in the Zoo" event on June 28th, this simple step challenge is a perfect way to download and experience the app for free whilst challenging yourself at the same time.

With some excellent prizes attached the challenge runs for two weeks starting on the 13th June. Sign up today via this link:

The Crowdfinders Charity Exercise Challenge
(please select 'Crowdfinders' from the drop down box)

Who's Who in the Zoo...? Biosignatures, that's Who!



Cancer is something that will affect most of us at some point during our lives, either as a patient or when supporting a family member or close friend with their cancer journey. Survival rates are improving, although still lag other countries, and a big part of that improvement is a result of raising cancer awareness to encourage early diagnosis. This year alone there have been some high-profile campaigns about prostate cancer from public figures such as Stephen Fry and Bill Turnbull coinciding with an announcement by Theresa May of £75m of investment to improve the diagnosis and treatment of prostate cancer. This has been followed, after the recent sad passing of Dame Tessa Jowell, by an additional £40m of investment by the Government, on top of an already committed £25m, to improve the diagnosis and treatment of brain cancer.

Given this Government support and the magnificent work being done daily by cancer charities, support organisations and healthcare professionals, we can all be hopeful that cancer awareness and survival rates will continue to improve.

Hopefully, cancer will not affect you or your loved ones and maybe it's something you don't think about too much. However, here at Biosignatures, we are thinking about cancer diagnosis all the time. Why? Because it could be so much better and we're on a mission to make it so.

The primary problem we are trying to solve is that particularly for cancer, a biopsy is often needed to get a final diagnosis. This is expensive, painful and often inaccurate. Biosignatures' vision is to replace biopsies with relatively cheap, non-invasive blood tests for as many patients as possible, reducing costs, enabling more patients to be cared for by the same resource, and improving the patient experience.

We do this by finding markers in the blood using the scientific technique called proteomics. We have solved the underlying problems in how to discover large numbers of new clinical products using proteomics by combining large sample datasets with a uniquely rigorous quality control process in our own laboratory and analysed by our unique, patented machine learning software.

Our first test for prostate cancer has passed a blind clinical trial and outperforms existing tests that are based on PSA by a significant margin. Post-trial analysis of the results has further improved this performance uplift demonstrating that the adoption of our test in the clinic would not only meet a defined clinical need, it would result in a significant reduction in the number of unnecessary biopsies – **almost 50% of men could be saved from having a prostate biopsy that they don't need**. That's great for the patient and great for the NHS. Furthermore, as people live longer, cancer, as a disease of aging will become more prevalent, so it will be even more important to ensure we reduce over treatment so that finite resources can be directed to those that really need them.

However, developing new cancer diagnostics takes time and money. Over the last 10 years, with funding from our founder and angel investors, we've developed our discovery process and machine learning software (so we aren't just jumping on the AI bandwagon!) and proven its effectiveness with our prostate test. But, to continue this work, complete the development of the prostate test, take it to market and develop tests for other cancers, we need more money and that's why we're fund raising now.

Will Dracup, the founder and CEO of Biosignatures, will be presenting at Who's Who in the Zoo - where you will be able to hear more about this exciting, innovative company and about the opportunity to invest in a truly novel cancer diagnostic that will one day change the face of prostate cancer diagnosis (and many other cancers after that).

For Sponsorship opportunities please contact **Tim Mangnall**

Book Now with our amazing '25%' discount.

BOOK HERE

